- Home
- Applications
- canada
- tumor effect
Show results for
Refine by
Tumor Effect Product Applications Available In Canada
6 applications found
BOC Sciences is committed to supplying cost-effective products and services. We provide Halofuginone (Cas No:55837-20-2). More information, please visit the website: http://www.bocsci.com/halofuginone-cas-55837-20-2-item-84-71625.html ...
ByBOC Sciences based in Shirley, NEW YORK (USA)
The ability to create large, RF lesions has multiple applications in soft tissue and tumor ablation. For example, there is a clear, unmet need in the market for the treatment of liver cancer. ...
ByThermedical, Inc. based in Waltham, MASSACHUSETTS (USA)
Unlike conventional vaccination strategies, cancer vaccines are designed to mount responses against tumor-specific antigens, arising from somatic mutations specific to the cancer genome. They promise a highly tailored approach by targeting patient-specific ...
ByEnpicom B.V. based in s-Hertogenbosch, NETHERLANDS
Gastric cancer is a disease in which cancer cells form in the lining of the stomach. Almost all gastric cancers are adenocarcinomas, a cancer that begins in glandular tissue. Gastric cancer is often in an advanced stage when it is diagnosed. At this stage, it can often be treated, but rarely ...
ByAscelia Pharma AB based in Malmö, SWEDEN
Deliver the right cells to the patient on time. Maximize Functional Characterization of Your Precious T Cell Samples. The Opto™ Cell Therapy Development workflow accelerates the creation of better therapeutics by performing multiple functional assays across 1,000s of individual T cells in a matter of days. Deeply characterize, profile, and map your T cell populations at the single-cell level to directly link phenotype to gene ...
ByBruker Corporation based in Billerica, MASSACHUSETTS (USA)
The long-standing, successful use of radio-theranostics in imaging and therapy is based on targeting radiolabeled molecules to tumors or other diseased tissues. Over 10,000 hospitals worldwide use radioisotopes for in-vivo diagnosis or treatment, reaching around 35 million patients each year. The ideal cancer imaging tool is a homogenous conjugate with a precisely defined payload-to-carrier ratio, showing specific tumor-targeting with minimal side-effects and fast ...
ByNavigo Proteins GmbH based in Halle, GERMANY